• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    G1 Therapeutics Inc (NQ: GTHX )

    4.490 +0.050 (+1.13%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 574,426
    Open 4.560
    Bid (Size) 4.400 (50)
    Ask (Size) 4.490 (3)
    Prev. Close 4.440
    Today's Range 4.480 - 4.700
    52wk Range 1.080 - 5.000
    Shares Outstanding 42,705,532
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
    Via Benzinga
    GTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024
    GTHX stock results show that G1 Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +44.37%
    +44.37%
    1 Month
    -2.39%
    -2.39%
    3 Month
    +0.67%
    +0.67%
    6 Month
    +175.46%
    +175.46%
    1 Year
    +48.68%
    +48.68%

    More News

    Read More
    G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
    From G1 Therapeutics
    Via GlobeNewswire
    G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
    From G1 Therapeutics
    Via GlobeNewswire
    Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
    Via Benzinga
    Forecasting The Future: 5 Analyst Projections For G1 Therapeutics
    Via Benzinga
    Biotech Innovations Paving the Way in Breast Cancer Fight
    Via FinancialNewsMedia
    Topics Death
    Exposures Death Product Safety
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
    From G1 Therapeutics
    Via GlobeNewswire
    Why Is Breast Cancer-Focused G1 Therapeutics Stock Trading Lower Today?
    Via Benzinga
    Exposures Product Safety
    Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Evercore ISI Is Warming Up to NextEra Energy (NEE) Stock
    Via InvestorPlace
    UBS Just Upped Its Nvidia (NVDA) Stock Price Target
    Via InvestorPlace
    Why ZoomInfo Technologies Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Is Polished.com (POL) Stock Down 33% Today?
    Via InvestorPlace
    Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?
    Via InvestorPlace
    ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Arista Networks Reports Q4 Results, Joins Teradata, Lattice Semiconductor And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
    From G1 Therapeutics
    Via GlobeNewswire
    G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
    From G1 Therapeutics
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.